BioSpace News Archive

Catalent, Inc. announced that it had completed its acquisition of MaSTherCell Global Inc., positioning Catalent as a premier technology, development and manufacturing partner for innovators of advanced biotherapeutics.

TransEnterix, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, announced that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor.

Agile Therapeutics, Inc., a women’s healthcare company, announced that it has entered into a senior secured term loan credit facility with Perceptive Advisors to provide Agile with up to $35 million through term loans in three tranches.

Renowned Stanford University specialist joins Hoag to bring care for Marfan Syndrome and Related Conditions to the Jeffrey M. Carlton Heart & Vascular Institute

Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced updated results from the phase 1b/2 clinical trial EV-103 in previously untreated patients with locally advanced or metastatic urothelial cancer who were ineligible for treatment with cisplatin-based chemotherapy.

Exelixis, Inc. (NASDAQ:EXEL) today announced encouraging results from the metastatic castration-resistant prostate cancer (CRPC) cohort of COSMIC-021, the phase 1b trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with locally advanced or metastatic solid tumors.

In the battle against deadly diseases that adapt quickly to resist today’s top antibiotics, researchers from the University of Nevada, Reno have shown that stopping bacterial cells from communicating can actually prevent them from amassing their lethal armies.

An innovative approach to tackling the challenges of pediatric sarcomas is being pursued by researchers at St. Jude Children’s Research Hospital (Memphis, Tennessee) with a new grant from Alliance for Cancer Gene Therapy (ACGT).

GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that Scott Mendel, Chief Operating Officer, has been appointed Interim President and Chief Executive Officer effective immediately.

Healthcare veteran to lead innovative SaaS platform to expanded reach, increased revenue